|
Market Closed -
NYSE
16:00:02 2026-09-10 EDT
|
5-day change | 1st Jan Change | ||
| 26.15 USD | -8.21% |
|
-13.21% | +9.74% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Developing and Commercializing Immunotherapies | 383M | 112M | 117M | 258M | 247M | |||||
Total Assets | 1.59B | 1.34B | 1.1B | 1.15B | 1.14B | |||||
Interest Expense | -260K | -2M | -2M | -4M | -8M | |||||
Income Tax Expense | 1.82M | 1M | 6M | 1M | - | |||||
CAPEX | -26.08M | -12M | -24M | -6M | -2M | |||||
EBT | 54.64M | -266M | -301M | -282M | -353M | |||||
D&A | 3.84M | 6M | 8M | 10M | 10M | |||||
Operating Income | 54.25M | -280M | -340M | -330M | -386M | |||||
Net Income | 52.83M | -267M | -307M | -283M | -353M |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 383M | 112M | 117M | 258M | 247M | |||||
Total Assets | 1.59B | 1.34B | 1.1B | 1.15B | 1.14B | |||||
Interest Expense | -260K | -2M | -2M | -4M | -8M | |||||
Income Tax Expense | 1.82M | 1M | 6M | 1M | - | |||||
D&A | 3.84M | 6M | 8M | 10M | 10M | |||||
CAPEX | -26.08M | -12M | -24M | -6M | -2M | |||||
Net Income | 52.83M | -267M | -307M | -283M | -353M | |||||
EBT | 54.64M | -266M | -301M | -282M | -353M | |||||
Operating Income | 54.25M | -280M | -340M | -330M | -386M |
- Stock Market
- Stocks
- RCUS Stock
- Financials Arcus Biosciences, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
